



April 11, 2023

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning an Alliance Agreement for Distribution and Sales of ARCT-154,  
Next Generation mRNA Vaccine for COVID-19, in Japan

Meiji Holdings Co., Ltd. announces that its subsidiary, Meiji Seika Pharma Co., Ltd. and CSL Seqirus<sup>\*1</sup>, a subsidiary of CSL Limited, have entered into a distribution agreement (the “Agreement”) for the distribution and sales of ARCT-154, a next generation mRNA COVID-19 vaccine, in Japan on April 11, 2023. CSL Seqirus has exclusively licensed worldwide rights to the vaccine, ARCT-154, from Arcturus Therapeutics Inc.<sup>\*2</sup>

Under the terms of the Agreement, Meiji Seika Pharma will be responsible for obtaining regulatory approval, distribution, sale and marketing of ARCT-154 in Japan. Meiji Seika Pharma will receive data from CSL Seqirus necessary for the development and regulatory submission of ARCT-154 and will pay an upfront payment.

ARCT-154 is a next generation mRNA vaccine and is potentially effective against SARS-CoV-2 variants including the Omicron variant. It is also expected that the dose of inoculation is small and the effect of the vaccine is long-lasting. Meiji Seika Pharma also has an ongoing Phase III booster clinical trial in Japan since December 13, 2022.

Meiji Seika Pharma has a collaboration with ARCALIS, Inc.<sup>\*3</sup> to establish an integrated manufacturing from drug substance to drug product in Japan. ARCALIS is building a manufacturing facility in Minami-soma City, Fukushima Prefecture.

Meiji Seika Pharma is working for supply it in Japan as soon as possible. It will become a new vaccination option against COVID-19.

The impact on the consolidated financial results for the fiscal year ending March 31, 2024, has not been determined at this time. We will closely examine the situation and disclose the impact as soon as it is recognized.

\*1: CSL Seqirus, a subsidiary of CSL Limited, is one of the world's largest suppliers of influenza vaccines. The company has state-of-the-art manufacturing facilities in the U.S., U.K., and Australia. It also has excellent research and development capabilities.  
(<https://www.cslseqirus.com/>)

Disclaimer: This English translation is prepared for the readers' convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.

\*2: Arcturus Therapeutics Holdings Inc. founded in 2013, is a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. (<https://arcturusrx.com/>)

\*3: ARCALIS, Inc. is a joint venture company between Axcelead Co., Ltd. and Arcturus Therapeutics Inc., which owns a group of world-class drug-discovery and healthcare platform companies. The company provides drug discovery support, as well as a contract development and manufacturing business (CDMO business), for mRNA medicines and vaccines. (<https://corp.arcalis.co.jp/en>)

#####